2Suppliers
6Customers
3Debt Items
20Related Chains

TherapeuticsMD, Inc. Suppliers

TickerNameConfidenceEvidence
ORANY ORANY 72% of the net working capital allowance for returns. In August 2024, the Company received information from Mayne Pharma pertaining to the net working capital allowance for returns that differs significa…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from TXMD graph: of the net working capital allowance for returns. In August 2024, the Company received information from Mayne Pharma…

TherapeuticsMD, Inc. Customers

TickerNameConfidenceEvidence
MAYNE-PHARMA MAYNE-PHARMA 92% The rant of the licenses under the Mayne License Agreement was (i) a cash payment of $140.0 million at closing, (ii) a cash payment of approximately $12.1 million at closing for the acquisition of ne…
KNIGHT-THERAPEUTICS-INC KNIGHT-THERAPEUTICS-INC 90% In July 2018, we entered into a license and supply agreement (the "Knight License Agreement") with Knight Therapeutics Inc. ("Knight") pursuant to which we granted Knight an exclusive license to comm…
THERAMEX-HQ-UK-LIMITED THERAMEX-HQ-UK-LIMITED 90% In June 2019, we entered into an exclusive license and supply agreement (the "Theramex License Agreement") with Theramex HQ UK Limited ("Theramex") to commercialize IMVEXXY and BIJUVA outside of the …
MAYNE-PHARMA-GROUP MAYNE-PHARMA-GROUP 80% If Mayne Pharma's sales of Licensed Products grow more slowly than expected or decline, including as a result of Mayne Pharma Group's potential sale to Cosette Pharmaceuticals, Inc.
ORANY ORANY 72% al product is a one-year ring-shaped contraceptive vaginal system (“CVS”) and the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy f…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from TXMD graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from TXMD graph: al product is a one-year ring-sha…

TherapeuticsMD, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
TXMD-DEBT Debt stack $4.8M 90% Market cache reports total debt of $4.8M.
TXMD-DEBT-13175 Warrants outstanding: 6534687 90% xbrl warrant detail from xbrl 2023-12-31.
TXMD-DEBT-13176 Xbrl Convertible 90% xbrl convertible detail from xbrl 2012-12-31.

TherapeuticsMD, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for TherapeuticsMD, Inc..

TherapeuticsMD, Inc. Ownership

HolderNameConfidenceEvidence
TXMD-OWNER-RUBRIC-CAPITAL-MANAGEMENT-LP Rubric Capital Management LP 90% 13F overlay lists Rubric Capital Management LP as top holder; 51 tracked holders.

TherapeuticsMD, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ORANY ORANGE 100.00 1 ['customer', 'supplier']
AMZE Amaze Holdings, Inc. 50.00 2
DWTX Dogwood Therapeutics, Inc. 50.00 2
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
CHUC Charlie's Holdings, Inc. 50.00 2
CLNE Clean Energy Fuels Corp. 50.00 2
FENC Fennec Pharmaceuticals Inc. 50.00 2
EQR Equity Residential 50.00 2
CNOB ConnectOne Bancorp, Inc. 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
ESS Essex Property Trust, Inc. 50.00 2
ED Consolidated Edison, Inc. 50.00 2
SCNX Scienture Holdings, Inc. 50.00 2
CORT Corcept Therapeutics Incorporated 50.00 2
BLTE Belite Bio, Inc 50.00 2